| Item |
Monday, February 20, 2017 |
| |
Neuroscience |
| 28461 |
Neurobiology of Addiction James A. Morrill, MD, PhD |
| 28462 |
Genetics of Substance Use Disorders Robert R. Althoff, MD, PhD |
| 28463 |
Neuroscience Panel Discussion David H. Rubin, MD; James A. Morrill, MD, PhD; Robert R. Althoff, MD, PhD |
| |
Empirically Based Methodologies I |
| 28464 |
Motivational Interviewing John F. Kelly, PhD |
| 28465 |
CBT John F. Kelly, PhD |
| 28466 |
Contingency Management Robert R. Althoff, MD, PhD |
| 28467 |
Empirically Based Methodologies I Panel Discussion
Timothy E. Wilens, MD; John F. Kelly, PhD; Robert R. Althoff, MD, PhD |
| |
Developmental Perspectives |
| 28468 |
Childhood Precursors Robert R. Althoff, MD, PhD |
| 28469 |
Adolescence Timothy E. Wilens, MD |
| 28470 |
Developmental PerspectivesPanel Discussion
David H. Rubin, MD; Robert R. Althoff, MD, PhD; Timothy E. Wilens, MD |
| |
Pharmacotherapy I |
| 28471 |
Managing Complicated Withdrawal Shamim H. Nejad, MD |
| 28472 |
Nicotine James A. Morrill, MD, PhD |
| 28473 |
Methamphetamine, Cocaine, Stimulants Timothy E. Wilens, MD |
| 28474 |
Pharmacotherapy I Panel Discussion Timothy E. Wilens, MD; Shamim H. Nejad, MD; James A. Morrill, MD, PhD |
| |
Comorbidity I |
| 28475 |
Mood Disorders Shamim H. Nejad, MD |
| 28476 |
Hepatitis C / HIV James A. Morrill, MD, PhD |
| 28477 |
Anxiety Disorders Shamim H. Nejad, MD |
| 28478 |
Comorbidity I Panel Discussion Timothy E. Wilens, MD; Shamim H. Nejad, MD; James A. Morrill, MD, PhD |
| Item |
Tuesday, February 21, 2017 |
| |
Recovery Oriented Systems of Care |
| 28479 |
Recovery Models of Care John F. Kelly, PhD |
| 28480 |
Treating Addiction as a Chronic Disease Sarah E. Wakeman, MD |
| 28481 |
Recovery Oriented Systems of Care Panel Discussion
Timothy E. Wilens, MD; John F. Kelly, PhD; Sarah E. Wakeman, MD |
| |
Marijuana, Synthetics, and Triple C-Legal and Illegal |
| 28482 |
Medical Marijuana Timothy E. Wilens, MD |
| 28483 |
Management of Marijuana Addiction Martha T. Kane, PhD |
| 28484 |
OCT: Synthetics and Triple-C Timothy E. Wilens, MD |
| 28485 |
Marijuana, Synthetics, and Triple C-Legal and Illegal Panel Discussion
Laura G. Kehoe, MD, MPH; Timothy E. Wilens, MD; Martha T. Kane, PhD |
| |
Empirically Based Methodologies II |
| 28486 |
Trauma Informed Care Martha T. Kane, PhD |
| 28487 |
Self-Help Treatments John F. Kelly, PhD |
| 28488 |
Empirically Based Methodologies II Panel Discussion
Laura G. Kehoe, MD, MPH; John F. Kelly, PhD; Martha T. Kane, PhD |
| |
Comorbidity II |
| 28489 |
ADHD Timothy E. Wilens, MD |
| 28490 |
Pain Laura G. Kehoe, MD, MPH |
| 28491 |
Comorbidity II Panel Discussion Sarah E. Wakeman, MD; Timothy E. Wilens, MD; Laura G. Kehoe, MD, MPH |
| Item |
Wednesday, February 22, 2017 |
| |
Inpatient |
| 28492 |
Substance Use Disorder Initiative: MGH Model Sarah E. Wakeman, MD |
| 28493 |
Inpatient Nursing in Addiction Care Christopher J. Shaw, NP |
| 28494 |
InpatientPanel Discussion Laura G. Kehoe, MD, MPH; Christopher J. Shaw, NP; Sarah E. Wakeman, MD |
| |
Empirically Based Methodologies III |
| 28495 |
Screening and Assessment Christopher J. Shaw, NP |
| 28496 |
Harm Reduction Sarah E. Wakeman, MD |
| 28497 |
Empirically Based Methodologies III Panel Discussion
Laura G. Kehoe, MD, MPH; Sarah E. Wakeman, MD; Christopher J. Shaw, NP |
| |
Pharmacotherapy II |
| 28498 |
Opioids Sarah E. Wakeman, MD |
| 28499 |
Alcohol Laura G. Kehoe, MD, MPH |
| 28500 |
Sedatives and Hypnotics David H. Rubin, MD |
| 28501 |
Pharmacotherapy II Panel Discussion David H. Rubin, MD; Sarah E. Wakeman, MD; Laura G. Kehoe, MD, MPH |
